Strategic combination of a PHGDH inhibitor with glucose restriction or free sialic acid treatment synergistically disrupts SerT/GluT clustering organization, amplifying the anti-tumor efficacy of the PHGDH inhibitor and establishing the metabolic plasticity of transporter assemblies as a targetable vulnerability. This evidence concerns the gene SLC2A1 and neoplasm.